Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"… Read more
Elicio Therapeutics Inc. (ELTX) - Total Assets
Latest total assets as of September 2025: $28.28 Million USD
Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) holds total assets worth $28.28 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Elicio Therapeutics Inc. - Total Assets Trend (2012–2024)
This chart illustrates how Elicio Therapeutics Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Elicio Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Elicio Therapeutics Inc.'s total assets of $28.28 Million consist of 73.4% current assets and 26.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 62.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Elicio Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elicio Therapeutics Inc.'s current assets represent 73.4% of total assets in 2024, an increase from 18.7% in 2012.
- Cash Position: Cash and equivalents constituted 62.5% of total assets in 2024, up from 12.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Elicio Therapeutics Inc. Competitors by Total Assets
Key competitors of Elicio Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Elicio Therapeutics Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Elicio Therapeutics Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Elicio Therapeutics Inc. is currently not profitable relative to its asset base.
Elicio Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.29 | 3.40 | 0.19 |
| Quick Ratio | 3.29 | 3.40 | 0.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.95 Million | $ 21.63 Million | $ -65.49 Million |
Elicio Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Elicio Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 58.34 |
| Latest Market Cap to Assets Ratio | 5.10 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | $28.18 Million |
| Market Capitalization | $143.62 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Elicio Therapeutics Inc.'s assets at a significant premium ( 5.10x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Elicio Therapeutics Inc.'s assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Elicio Therapeutics Inc. (2012–2024)
The table below shows the annual total assets of Elicio Therapeutics Inc. from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $28.18 Million | +3.80% |
| 2023-12-31 | $27.15 Million | +19.78% |
| 2022-12-31 | $22.66 Million | -76.52% |
| 2021-12-31 | $96.51 Million | +103.84% |
| 2020-12-31 | $47.35 Million | +298.34% |
| 2019-12-31 | $11.89 Million | -55.36% |
| 2018-12-31 | $26.63 Million | +140.70% |
| 2013-12-31 | $11.06 Million | +0.30% |
| 2012-12-31 | $11.03 Million | -- |